Mark L Metersky (University of Connecticut School of Medicine, Farmington, CT, US) discusses current recommendations and guidelines with respect to the use of empiric antibiotic therapy in patients with ventilator-associated pneumonia.
Questions1. What are the major challenges of empiric antibiotic therapy in patients with ventilator-associated pneumonia? (0:10)
2. How are patients defined in terms of risk when selecting antibiotic treatment? (1:49)
3. What are the recommendations of the latest guidelines in the treatment of patients with risk factors for multidrug resistance and high mortality risk? (2:59)
4. What is the current recommended antibiotic treatment duration for high- and low-risk patients? (3:25)
5. What are the limitations of the current guidelines? (6:03)
Speaker disclosure: Mark L Metersky has nothing to disclose in relation to this video interview.
Filmed at the CHEST Annual Meeting, San Antonio, TX, US, October 2018.